Skip to main content

Table 3 Relative changes in plasma parameters upon insulin-stimulation during the hyperinsulinemic-euglycemic clamp

From: Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus

  Diabetic patients (n = 11) Controls (n = 10)
  Before treatment After treatment  
Albumin (%) -3.4 ± 0.9# -3.1 ± 1.1# -6.0 ± 0.8#
Total cholesterol (%) 0.4 ± 0.8 -1.7 ± 1.4 0.4 ± 0.7
LDL cholesterol (%) 2.5 ± 2.1 -0.5 ± 1.3 2.3 ± 1.1
HDL cholesterol (%) 1.3 ± 2.7 0.8 ± 1.6 2.7 ± 1.3
Triglycerides (%) -5.2 ± 6.4 -14.3 ± 5.5a,c -16.7 ± 4.5a
FFA (%) -58.9 ± 3.4a,b -65.0 ± 4.1a,c -80.1 ± 2.6a
hsCRP (%) -4.7 ± 2.7 -4.9 ± 2.4 5.5 ± 4.5
TNFα (%) 12.0 ± 6.6 -9.1 ± 7.9c 12.1 ± 14.2
IL6 (%) 13.7 ± 6.7 16.4 ± 7.9 23.5 ± 9.0a
MCP1 (%) -9.1 ± 1.8a -3.7 ± 4.0 -11.1 ± 4.1a
  1. # Plasma albumin changed (p < 0.05) during the clamp because of increase in blood volume due to fluid infusion. Therefore, all plasma parameters are corrected for changes in plasma albumin concentration and presented as mean ± SEM
  2. a Significant change (P < 0.05) in response to insulin
  3. b Significant difference between type 2 diabetic patients and BMI-matched controls in response to insulin
  4. c Significant change (P < 0.05) effect of rosiglitazone treatment on the response to insulin in type 2 diabetic patients